PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Added To NASDAQ Biotechnology Index
ROCKVILLE, Md. --(BUSINESS WIRE)--Dec. 15, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that it will be included in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NASDAQ Biotechnology Index will be effective prior to market upon on Monday, December 18, 2017 .
View HTML
Toggle Summary GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271
Clinical outcomes, including durability of remission and median overall survival, in high-risk patients plus safety and tolerability data presented in oral presentation at American Society of Hematology Annual Meeting and Expo Second oral presentation highlights underlying, differentiated mechanism
View HTML
Toggle Summary GlycoMimetics to Present at Upcoming Healthcare Investor Conferences
ROCKVILLE, Md. --(BUSINESS WIRE)--Nov. 9, 2017-- GlycoMimetics, Inc. (Nasdaq:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2017 HEALTHCARE CONFERENCE When: November 14, 2017 at 8:00
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and Third Quarter 2017 Results
Ongoing discussions with U.S. Food and Drug Administration ( FDA ) regarding regulatory path for GMI-1271, including planned Phase 3 trial initiation in mid-2018 Pro forma cash balance of $132.1 million as of September 30 Two abstracts accepted as oral presentations at the 2017 American Society of
View HTML
Toggle Summary GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017
ROCKVILLE, Md ,--(BUSINESS WIRE)--Nov. 1, 2017-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2017 financial results on Wednesday, November 8, 2017 , at 8:30 a.m. ET .
View HTML
Toggle Summary GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting
GMI-1271 improves efficacy and safety of chemotherapy in Phase 1/2 study in two acute myeloid leukemia (AML) patient populations Preclinical data detail underlying mechanism for GMI-1271’s ability to enhance sensitivity to chemotherapy GlycoMimetics will review the GMI-1271 clinical data during a
View HTML
Toggle Summary GlycoMimetics to Present at Biocentury's Newsmakers in the Biotech Industry Conference
ROCKVILLE, MD --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will present at BioCentury's Newsmakers in the Biotech Industry Conference. The presentation will take place on Friday, September 8, 2017 at 1:30 p.m.
View HTML
Toggle Summary GlycoMimetics Reports Program Updates and Second Quarter 2017 Results
FDA granted Breakthrough Therapy designation to the Company's drug candidate, GMI-1271, for treatment of adults with relapsed/refractory acute myeloid leukemia (AML) Company completed enrollment in the in Phase 2 portion of its Phase 1/2 trial of GMI-1271 for the treatment of AML Clinicians
View HTML
Toggle Summary GlycoMimetics to Receive European Patent for GMI-1271
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the European Patent Office has issued an "intention to grant" letter for European Patent Application Number EP12813711.1, titled "E-Selectin Antagonist Compounds, Compositions, and Methods of Use." This
View HTML
Toggle Summary GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
ROCKVILLE, Md. --(BUSINESS WIRE)--Jun. 12, 2017-- GlycoMimetics , Inc. (NASDAQ:GLYC) announced today the appointment of Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc. , to its Board of Directors. “It’s an asset to our Board and GlycoMimetics as a whole to be
View HTML